Friday Aug 1
Threshold Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
Revenue for the second quarter ended June 30, 2014 was $3.7 million. The operating loss for the second quarter ended June 30, 2014 was $7.5 million.
Threshold Announces Initiation Of Dosing With TH-302/Bortezomib In...
Threshold Pharmaceuticals, Inc. today announced that dosing has started in the final stage of an ongoing Phase 1/2 trial of its investigational hypoxia-activated prodrug, TH-302, in combination with the proteasome inhibitor bortezomib and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma, a cancer of the bone marrow.
Threshold Pharmaceuticals Coverage Initiated by Analysts at Brean Capital
The firm set a "buy" rating and a $15.00 price target on the stock. Brean Capital's price target would indicate a potential upside of 265.85% from the stock's previous close.
Threshold Initiates Phase 2 Clinical Trial In Advanced Non-Squamous Non-Small Cell Lung Cancer
Threshold initiated a Phase 2 trial with TH-302 for the treatment of advanced non-squamous non-small cell lung carcinoma .